Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection
Figure 3
CD4 IFN-γ ELISPOT profile by antigen and treatment arm.
Antiretroviral therapy was discontinued at study week 30. Positive responses were defined as a 2-fold increase from baseline that were also ≥100 spot forming cells (SFC) per million PBMC. The symbol V indicates when vaccine or placebo was administered. The shaded area indicates the time period when subjects were off antiretroviral therapy.